Annals of Laboratory Medicine

Korean Society for Laboratory Medicine (대한진단검사의학회)
권호 표지
DOI QR코드

DOI QR Code

Rapid Sequential Gain of ABL1 Kinase Domain Mutations with a Complex Karyotype in the Progression of Chronic Myelogenous Leukemia

  • Chung, Yousun (Department of Laboratory Medicine, Seoul National University Hospital) ;
  • Eom, Hyeon-Seok (Hematologic Oncology Clinic, Research Institute and Hospital, National Cancer Center) ;
  • Lee, Hyewon (Hematologic Oncology Clinic, Research Institute and Hospital, National Cancer Center) ;
  • Park, Sunseob (Hematologic Oncology Clinic, Research Institute and Hospital, National Cancer Center) ;
  • Shim, Hyoeun (Department of Laboratory Medicine, Research Institute and Hospital, National Cancer Center) ;
  • Cho, Eun Hae (Greencross Reference Laboratory) ;
  • Kong, Sun-Young (Department of Laboratory Medicine, Research Institute and Hospital, National Cancer Center)
  • Received : 2013.12.16
  • Accepted : 2014.06.09
  • Published : 2014.09.01
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054-61. https://doi.org/10.1038/leu.2009.38
  2. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002;359: 487-91. https://doi.org/10.1016/S0140-6736(02)07679-1
  3. Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, Lahaye T, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002;16:2190-6. https://doi.org/10.1038/sj.leu.2402741
  4. Soverini S, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica 2007;92:401-4. https://doi.org/10.3324/haematol.10822
  5. Hughes T, Saglio G, Branford S, Soverini S, Kim DW, Müller MC, et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009;27:4204-10. https://doi.org/10.1200/JCO.2009.21.8230
  6. Müller MC, Cortes JE, Kim DW, Druker BJ, Erben P, Pasquini R, et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 2009; 114:4944-53. https://doi.org/10.1182/blood-2009-04-214221
  7. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27: 6041-51. https://doi.org/10.1200/JCO.2009.25.0779
  8. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984;63:789-99.
  9. Hehlmann R, Ansari H, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, et al. Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. German chronic myeloid leukaemia (CML)-Study Group. Br J Haematol 1997;97: 76-85. https://doi.org/10.1046/j.1365-2141.1997.102652.x
  10. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80. https://doi.org/10.1126/science.1062538
  11. Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 2011;118: 1208-15. https://doi.org/10.1182/blood-2010-12-326405
  12. Ernst T, Gruber FX, Pelz-Ackermann O, Maier J, Pfirrmann M, Müller MC, et al. A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib. Haematologica 2009;94:1227-35. https://doi.org/10.3324/haematol.2009.006981
  13. Parker WT, Lawrence RM, Ho M, Irwin DL, Scott HS, Hughes TP, et al. Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy. J Clin Oncol 2011;29:4250-9. https://doi.org/10.1200/JCO.2011.35.0934
  14. Parker WT, Ho M, Scott HS, Hughes TP, Branford S. Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile. Blood 2012;119:2234-8. https://doi.org/10.1182/blood-2011-08-375535